

Atorvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 10/10/2020
3.5 04/09/2021 184693-00012 Date of first issue: 06/17/2015

SECTION 1. IDENTIFICATION

Product name : Atorvastatin Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
 Rahway, New Jersey U.S.A 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the Hazardous Products Regulations**

Specific target organ toxicity : Category 2 (Liver, muscle)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Precautionary Statements :
Prevention:
P260 Do not breathe dust.
Response:
P314 Get medical attention if you feel unwell.
Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Atorvastatin Formulation

Version 3.5 Revision Date: 04/09/2021 SDS Number: 184693-00012 Date of last issue: 10/10/2020
 Date of first issue: 06/17/2015

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Calcium carbonate	Carbonic acid calcium salt	471-34-1	>= 30 - < 60 *
Cellulose	No data available	9004-34-6	>= 10 - < 30 *
Atorvastatin	No data available	134523-03-8	>= 10 - < 30 *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
 Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.
 Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention if symptoms occur.
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.
 Contact with dust can cause mechanical irritation or drying of the skin.
 Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
 Exposure to combustion products may be a hazard to health.

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Atorvastatin Formulation

Version 3.5 Revision Date: 04/09/2021 SDS Number: 184693-00012 Date of last issue: 10/10/2020
 Date of first issue: 06/17/2015

- Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Calcium carbonate	471-34-1	TWAEV (total dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³ (Calcium carbonate)	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		STEL	20 mg/m ³	CA BC OEL
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Atorvastatin	134523-03-8	TWA	0.05 mg/m ³ (OEB 3)	Internal
		Wipe limit	0.5 mg/100 cm ²	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

	exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: granular
Color	: No data available
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: May form explosive dust-air mixture during processing, handling or other means.

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact

Atorvastatin Formulation

Version 3.5 Revision Date: 04/09/2021 SDS Number: 184693-00012 Date of last issue: 10/10/2020
Date of first issue: 06/17/2015

Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Calcium carbonate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 420
Assessment: The substance or mixture has no acute oral toxicity

Acute inhalation toxicity : LC50 (Rat): > 3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Atorvastatin:

Acute oral toxicity : LD50 (Rat, male and female): > 5,000 mg/kg
LD50 (Mouse, male and female): > 5,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Calcium carbonate:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Atorvastatin:

Species : Rabbit
Result : No skin irritation

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

Test Type: In vitro mammalian cell gene mutation test
 Method: OECD Test Guideline 476
 Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Atorvastatin:

Genotoxicity in vitro : Test Type: reverse mutation assay
 Test system: Salmonella typhimurium
 Result: negative

Test Type: reverse mutation assay
 Test system: Escherichia coli
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Test system: Chinese hamster lung cells
 Result: negative

Test Type: sister chromatid exchange assay
 Test system: Chinese hamster lung cells
 Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
 Species: Mouse
 Cell type: Bone marrow
 Application Route: Oral
 Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

Atorvastatin:

Species : Mouse, male and female
 Application Route : oral (gavage)
 Exposure time : 2 Years
 NOAEL : 200 mg/kg body weight
 LOAEL : 400 mg/kg body weight
 Result : negative
 Target Organs : Liver

Species : Rat, female
 Application Route : oral (gavage)
 Exposure time : 2 Years
 LOAEL : 100 mg/kg body weight
 Target Organs : Musculo-skeletal system

Reproductive toxicity

Not classified based on available information.

Components:

Calcium carbonate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 422
 Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Ingestion
 Method: OECD Test Guideline 414
 Result: negative

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Result: negative

Atorvastatin:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, female
 Fertility: NOAEL: 225 mg/kg body weight
 Result: No effects on fertility.

Test Type: Fertility/early embryonic development
 Species: Rat, male

Atorvastatin Formulation

Version 3.5 Revision Date: 04/09/2021 SDS Number: 184693-00012 Date of last issue: 10/10/2020
Date of first issue: 06/17/2015

Fertility: NOAEL: 175 mg/kg body weight
Result: No effects on fertility.

Effects on fetal development : Species: Rat, female
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: No teratogenic effects., Embryo-fetal toxicity.
Remarks: Maternal toxicity observed.

Species: Rabbit, female
Application Route: Oral
Developmental Toxicity: NOAEL: 100 mg/kg body weight
Result: No embryo-fetal toxicity.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Components:**Atorvastatin:**

Routes of exposure : Ingestion
Target Organs : Liver, muscle
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Calcium carbonate:**

Species : Rat
NOAEL : > 1,000 mg/kg
Application Route : Ingestion
Exposure time : 28 Days
Method : OECD Test Guideline 422

Cellulose:

Species : Rat
NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Atorvastatin:

Species : Rat, male and female
LOAEL : 70 mg/kg
Application Route : oral (gavage)
Exposure time : 52 Weeks
Target Organs : Liver

Species : Dog

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

LOAEL	:	10 mg/kg
Application Route	:	oral (gavage)
Exposure time	:	104 Weeks
Target Organs	:	Liver

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Atorvastatin:**

Ingestion	:	Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change
-----------	---	---

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Calcium carbonate:**

Toxicity to fish	:	LL50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	NOELR (Pseudokirchneriella subcapitata (green algae)): 50 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201
		EL50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201
Toxicity to microorganisms	:	NOEC: 1,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209
		EC50: > 1,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

Cellulose:

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
 Exposure time: 48 h
 Remarks: Based on data from similar materials

Atorvastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 92 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 200 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 108 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 14 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.49 mg/l
 Exposure time: 33 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.2 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Atorvastatin:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 7.7 %
 Exposure time: 28 d
 Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Atorvastatin:

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

Partition coefficient: n-octanol/water : log Pow: 1.62

Mobility in soil**Components:****Atorvastatin:**

Distribution among environmental compartments : log Koc: 2.84

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**TDG**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for air-borne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA BC OEL / STEL	:	short-term exposure limit
CA QC OEL / TWA EV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
--	---	---

Revision Date	:	04/09/2021
Date format	:	mm/dd/yyyy

SAFETY DATA SHEET



Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/10/2020
3.5	04/09/2021	184693-00012	Date of first issue: 06/17/2015

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8